---
$id: https://graph.org.ai/products/commodity/51201818
$type: Product
source: UNSPSC
code: "51201818"
title: "Roquinimex"
class: "51201800"
classTitle: "Immunostimulating agents"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Roquinimex

**UNSPSC Code**: 51201818
**Class**: [Immunostimulating agents](Immunostimulating agents.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an immunostimulant and angiogenesis activator inhibitor with the molecular formula C18H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 372T2944C0, chemically known as 1,2-dihydro-4-hydroxy-n,1-dimethyl-2-oxo-3-quinolinecarboxanilide but generally known as roquinimex, which bears US NIH Compound Identifier 55197. European Medicines Agency schedules Roquinimex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10384MIG. The term ROQUINIMEX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules roquinimex in its Anatomical Therapeutic Chemical (ATC) Classification. ROQUINIMEX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roquinimex under HS 29337900 and SITC 51561. As of Q4 2014, ROQUINIMEX remains the US FDA Preferred Term for this commodity. Roquinimex bears US NLM identifiers UMLS ID C0244748 and NCI Concept Code C1519. SMILES: OC1N(C2C(C(=O)C1C(=O)N(C1CCCCC1)C)CCCC2)C.

